Follicular lymphoma: an Institutional Analysis

about

Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group

P2860

Q58801965-FF791EEA-1306-490C-A72C-D9B34CED4039

P2860

Follicular lymphoma: an Institutional Analysis

Item

http://www.wikidata.org/entity/Q38820935

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Follicular lymphoma: an Institutional Analysis

@en

type

Item

label

Follicular lymphoma: an Institutional Analysis

@en

prefLabel

Follicular lymphoma: an Institutional Analysis

@en

P1476

Follicular lymphoma: an Institutional Analysis

@en

P2093

Ajay Gogia

http://www.w3.org/2001/XMLSchema#string

Atul Sharma

http://www.w3.org/2001/XMLSchema#string

Lalit Kumar

http://www.w3.org/2001/XMLSchema#string

Mehar Chand Sharma

http://www.w3.org/2001/XMLSchema#string

Saumya Ranjan Mallick

http://www.w3.org/2001/XMLSchema#string

Vinod Raina

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.

Cancer incidences in rural Delhi--2004-05.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

P304

681-685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.22034/APJCP.2017.18.3.681

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28440975

http://www.w3.org/2001/XMLSchema#string

P932

5464484

http://www.w3.org/2001/XMLSchema#string

Follicular lymphoma: an Institutional Analysis

about

P2860

P2860

Follicular lymphoma: an Institutional Analysis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932